Higher Risks of Gastrointestinal Effects in Diabetic Patients In October 2023, The Journal of the American Medical Association(JAMA), examined adverse events in patients with diabetes associated with GLP-1 RA in a research letter called Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss where it concluded that studies have found increased risks of gastrointestinal adverse events, such as biliary disease, pancreatitis, bowel obstruction, and gastroparesis
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jni P, Lettino M, Marx N, Mellbin LG, stgren CJ, Rocca B, Roffi M, Sattar N, Seferovi PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group
| Antonio et al
Explore Innovative Solutions for IBS At Tulsi Wellness Club, we are excited about the potential of BPC-157 to offer new avenues for managing IBS and supporting digestive health
The Science Behind Mounjaro GI Effects Mounjaro (tirzepatide) works by activating both GIP and GLP-1 receptors